CTOs on the Move

Triosyn Research Inc

www.triosyn.com

 
Triosyn Research Inc is a Mirabel, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.triosyn.com
  • 14163 boul du Curí©-Labelle
    Mirabel, QC CAN J7J 1M3
  • Phone: 450.434.6099

Executives

Name Title Contact Details

Similar Companies

Corium International

Corium International is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoDa Therapeutics

CoDa Therapeutics, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Allied Biotech

Allied Biotech is a Ijamsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Miragen Therapeutics

miRagen Therapeutics, Inc., is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. From its founding, miRagen has developed ongoing, collaborative relationships with academic institutions that give the company unique access to the most promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of miRNA-targeting therapeutics.